Bilaketaren emaitzak - Jeffrey A. Zonder

Findu emaitzak
  1. 1
    Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

    Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin... nork Q. Ping Dou, Jeffrey A. Zonder

    Argitaratua 2014
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Clinical development of novel proteasome inhibitors for cancer treatment

    Clinical development of novel proteasome inhibitors for cancer treatment nork Huanjie Yang, Jeffrey A. Zonder, Q. Ping Dou

    Argitaratua 2009
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Exportin 1 inhibition as antiviral therapy

    Exportin 1 inhibition as antiviral therapy nork Md. Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi

    Argitaratua 2020
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Circular RNAs in acute myeloid leukemia

    Circular RNAs in acute myeloid leukemia nork Vijendra K. Singh, Md. Hafiz Uddin, Jeffrey A. Zonder, Asfar S. Azmi, Suresh Kumar Balasubramanian

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

    Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis nork Jeffrey A. Zonder, Bart Barlogie, Brian G.M. Durie, Jason McCoy, John Crowley, Mohamad A. Hussein

    Argitaratua 2006
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

    Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety nork Ashraf Badros, Ravi Vij, Thomas C. Martin, Jeffrey A. Zonder, Lori Kunkel, Z. Wang, S. Lee, Alvin Wong, Rubén Niesvizky

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

    A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma nork Jeffrey A. Zonder, Ann Mohrbacher, Seema Singhal, Frits van Rhee, William Bensinger, Han Ting Ding, John Fry, Daniel Afar, Anil Singhal

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

    Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study nork Suzanne Lentzsch, Galina Lagos, Raymond L. Comenzo, Jeffrey A. Zonder, Keren Osman, Samuel Pan, Divaya Bhutani, Silva Pregja, Vaishali Sanchorawala, Heather Landau

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

    Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) nork Jeffrey A. Zonder, John Crowley, Mohamad A. Hussein, Vanessa Bolejack, Dennis F. Moore, Brock Whittenberger, Muneer H. Abidi, Brian G.M. Durie, Bart Barlogie

    Argitaratua 2010
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

    Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma nork Shaji Kumar, Betsy LaPlant, Wee Joo Chng, Jeffrey A. Zonder, Natalie S. Callander, Rafaël Fonseca, Briant Fruth, Vivek Roy, Charles Erlichman, A. Keith Stewart

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

    Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase... nork Jesús G. Berdeja, Sundar Jagannath, Jeffrey A. Zonder, Ashraf Badros, Jonathan L. Kaufman, Robert Manges, Manish Gupta, Amol Tendolkar, Mark Lynch, Eric Bleickardt, Prashni Paliwal, Ravi Vij

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

    The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function nork Meletios Α. Dimopoulos, Adrián Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, Donna Reece, Marta Olesnyckyj, Zhinuan Yu, Donna M. Weber

    Argitaratua 2010
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

    Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials nork Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander K. Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z. Orlowski, S. Vincent Rajkumar

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

    A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma nork Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William Bensinger, Brandi Hilder, Selena Rush, Duncan Walker, Brian Tunquist, Kevin Litwiler, Mieke Ptaszynski, Robert Z. Orlowski, Sagar Lonial

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Daratumumab proves safe and highly effective in <scp>AL</scp> amyloidosis

    Daratumumab proves safe and highly effective in <scp>AL</scp> amyloidosis nork Jack Khouri, Andrew Kin, Bicky Thapa, Frederic J. Reu, Naresh Bumma, Christy Samaras, Hien Liu, Mary Ann Karam, Janice Reed, Saveta Mathur, Beth Faiman, Georgia Devries, Jeffrey A. Zonder, Jason Valent

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)

    The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus state... nork Charalampia Kyriakou, Sean Molloy, Frank D. Vrionis, Ronald Alberico, L. Bastian, Jeffrey A. Zonder, Sergio Giralt, Noopur Raje, Robert A. Kyle, David Roodman, Meletios Α. Dimopoulos, S. Vincent Rajkumar, Brian Durie, Evangelos Terpos

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent

    Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent nork Benjamin A. Derman, Ankit Kansagra, Jeffrey A. Zonder, Andrew Stefka, David L. Grinblatt, Larry D. Anderson, Sandeep Gurbuxani, Sunil Narula, Shayan Rayani, Ajay Major, Andrew Kin, Ken Jiang, Theodore Karrison, Jagoda Jasielec, Andrzej Jakubowiak

    Argitaratua 2022
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

    First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction nork Morie A. Gertz, Heather Landau, Raymond L. Comenzo, David C. Seldin, Brendan M. Weiss, Jeffrey A. Zonder, Giampaolo Merlini, Stefan Schönland, Jackie Walling, Gene G. Kinney, Martin Koller, Dale B. Schenk, Spencer Guthrie, Michaela Liedtke

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

    A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis nork Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai-Min Hui, Raymond L. Comenzo, Giampaolo Merlini

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

    Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients nork Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Charles Du Mond, Eftathios Kastritis, Heather Landau, Edward N. Libby, Michaela Liedtke, Giampaolo Merlini, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Gene G. Kinney

    Argitaratua 2019
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: